DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/042f10/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.
Business Monitor International's Sweden Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Sweden's pharmaceuticals and healthcare industry.
BMI View:
Sweden's high public expenditure on health (SEK252bn, or US$39bn, in 2011), accounting for 79% of total healthcare expenditure) is a major factor in making it an attractive place to sell medicines. Furthermore, given the country's high per capita drug expenditure (US$699 in 2011), BMI believes pharmaceuticals will continue to bring in substantial income for companies operating in the country.
Risk/Reward Rating:
Sweden's strong emphasis on the regulatory environment is a draw, though a major factor affecting the business environment for drugmakers is its small overall market size, which - combined with pressure on pharmaceutical spending - negatively affects the industry rewards score in particular. Nevertheless, given its high per capita drug expenditure, medicines continue to bring in substantial income for companies in the country.
Key Trends and Developments:
In December 2011, UK biotechnology company GW Pharmaceuticals secured approval from the Swedish Medical Products Agency (MPA) for its oromucosal spray Sativex (delta-9- tetrahydrocannabinol and cannabidiol). The spray is designed to treat moderate-to-severe spasticity due to multiple sclerosis (MS) in patients who have not responded to other antispasticity medications. It is likely to be released in H112 after the conclusion of the national pricing and reimbursement process.
Key Topics Covered:
- Executive Summary
- SWOT Analysis
- Sweden. Market Summary
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Sweden Demographic Data
- Glossary
- BMI Methodology
Companies Mentioned:
- Meda
- Swedish Orphan Biovitrum
For more information visit http://www.researchandmarkets.com/research/042f10/sweden_pharmaceuti